Source link : https://www.newshealth.biz/health-news/t-dxd-preserves-qol-brain-function-in-her2-breast-cancer/
SAN ANTONIO — More than half of patients with pretreated HER2-positive advanced or metastatic breast cancer who received the antibody-drug conjugate trastuzumab deruxtecan (T-DXd; Enhertu) had preservation of health-related quality of life (HRQOL) and neurological function at 1 year, even when the cancer had metastasized to brain, an analysis of data from the DESTINY-Breast12 trial […]
Author : News Health
Publish date : 2024-12-20 07:24:45
Copyright for syndicated content belongs to the linked Source.